<DOC>
	<DOCNO>NCT01272765</DOCNO>
	<brief_summary>This pilot study determine safety efficacy investigational product ( IHBG-10 ) weight change change body composition subject take stable dose certain anti-psychotic medication longer three month .</brief_summary>
	<brief_title>Anti-psychotic Medication ( Stable Dose ) Weight Loss Study</brief_title>
	<detailed_description>A total 80 subject enrol study : 20 subject randomize receive placebo , 60 randomize receive investigational product ( 20 stable dose Seroquel , 20 stable dose Risperdal , 20 stable dose Zyprexa ) . The investigational product placebo take 15 minute prior three main meal day . Subjects continue take prescribed anti-psychotic medication . Participation study involve four study visit .</detailed_description>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Men woman , age 18 old Agree keep diet , exercise current health habit stable participation study Currently stable dose Risperdal ( Risperidone ) , Seroquel ( Quetiapine ) and/or Zyprexa ( Olanzapine ) least three month Current active acute psychotic episode Women pregnant , breastfeeding , plan become pregnant Prior bariatric surgery Use prescription overthecounter appetite suppressant , herbal product medication weight loss within past month Obesity result clinicallydiagnosed endocrine problem</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>weight management</keyword>
	<keyword>anti-psychotic medication</keyword>
	<keyword>Zyprexa</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Risperdal</keyword>
</DOC>